Cargando…

Management of bone metastases in refractory prostate cancer – role of denosumab

This article reviews the problem of bone disease in prostate cancer and the evolving role of the novel agent denosumab, a fully human monoclonal antibody that inhibits the receptor activator of nuclear factor-κB ligand, in suppressing bone resorption and offering bone protection in this disease. Pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paller, Channing J, Carducci, Michael A, Philips, George K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459574/ https://www.ncbi.nlm.nih.gov/pubmed/23049248 http://dx.doi.org/10.2147/CIA.S27930

Ejemplares similares

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

A Review of Pomegranate in Prostate Cancer
por: Paller, Channing J., et al.
Publicado: (2017)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
por: Paller, Channing J, et al.
Publicado: (2011)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2020)

Denosumab-related osteonecrosis of the jaw in a patient with bone metastases of prostate cancer: A case report and literature review
por: Yoshimura, Hitoshi, et al.
Publicado: (2017)

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Multimodality treatment in hormone-refractory prostate cancer patients with bone metastases
por: Lam, Marnix G. E. H., et al.
Publicado: (2008)

Prostate cancer bone metastases biology and clinical management (Review)
por: Archer Goode, Emily, et al.
Publicado: (2023)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
por: Yee, Andrew J, et al.
Publicado: (2012)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
por: Li, Wei, et al.
Publicado: (2023)

Severe Refractory Hypocalcemia Caused by Denosumab
por: Dadana, Sriharsha, et al.
Publicado: (2023)

Giant-cell tumor of bone: treatment options and role of denosumab
por: Singh, Arun S, et al.
Publicado: (2015)

Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer
por: Dhabhar, Boman
Publicado: (2022)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
por: Ohlmann, Carsten-Henning
Publicado: (2012)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Diagnosis and Management of Denosumab-Induced Hypocalcemia and Hypophosphatemia in the Setting of Metastatic Prostate Cancer
por: Flood, Michael G, et al.
Publicado: (2022)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer
por: Cox, Heather, et al.
Publicado: (2015)

Prostate Cancer and Bone Metastases: The Underlying Mechanisms
por: Wong, Sok Kuan, et al.
Publicado: (2019)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience
por: Deek, Matthew P., et al.
Publicado: (2019)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Applications for open access normalized synthesis in metastatic prostate cancer trials
por: Luechtefeld, Thomas, et al.
Publicado: (2022)

The role of radiation therapy in bone metastases management
por: Felice, Francesca De, et al.
Publicado: (2017)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Refractory Shock Secondary to Denosumab-induced Severe Hypocalcaemia
por: Eshak, Nouran, et al.
Publicado: (2022)

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A ‘hypothesis-generator’ study from clinical practice
por: Cortellini, Alessio, et al.
Publicado: (2018)

Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report
por: Wang, Guannan, et al.
Publicado: (2019)

Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
por: Mizuta, Kohei, et al.
Publicado: (2023)

Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2021)

Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study
por: Abousaud, Aseala I., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8bls8ermtluebfhrh0incd0a5a